Nevertheless, both in terms of mechanisms of action and in light of existing research findings, there are compelling reasons to believe that HDAC3 inhibitors may serve as sensitizers when combined with immunotherapy, thereby enhancing the efficacy of immunotherapeutic approaches, underscoring the clinical value of tumor immunotherapy, and facilitating the exploration and development of novel clinical treatment strategies. This evidence concerns the gene HDAC3 and neoplasm.